$0.4299
+0.03
(+8.84%)▲
Insights on Dynatronics Corp
Revenue is down for the last 3 quarters, 9.35M → 7.65M (in $), with an average decrease of 9.5% per quarter
Netprofit is up for the last 2 quarters, -1.01M → -667.72K (in $), with an average increase of 51.5% per quarter
In the last 1 year, Boston Scientific Corp. has given 45.7% return, outperforming this stock by 95.4%
In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 172.9%
9.26%
Downside
Day's Volatility :14.99%
Upside
6.32%
13.86%
Downside
52 Weeks Volatility :59.3%
Upside
52.75%
Period | Dynatronics Corp | Index (Russel 2000) |
---|---|---|
3 Months | -11.38% | 0.0% |
6 Months | -25.25% | 0.0% |
1 Year | -49.75% | 0.0% |
3 Years | -93.33% | -22.6% |
Market Capitalization | 2.1M |
Book Value | $1.41 |
Earnings Per Share (EPS) | -1.21 |
PEG Ratio | 0.0 |
Wall Street Target Price | 4.0 |
Profit Margin | -13.07% |
Operating Margin TTM | -7.47% |
Return On Assets TTM | -8.31% |
Return On Equity TTM | -25.78% |
Revenue TTM | 33.6M |
Revenue Per Share TTM | 7.59 |
Quarterly Revenue Growth YOY | -17.1% |
Gross Profit TTM | 10.2M |
EBITDA | -2.7M |
Diluted Eps TTM | -1.21 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.92 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.26 |
What analysts predicted
Upside of 830.45%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 64.4M | ↑ 80.14% |
Net Income | -1.6M | ↓ 14.15% |
Net Profit Margin | -2.49% | ↑ 2.73% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 62.6M | ↓ 2.87% |
Net Income | -921.0K | ↓ 42.52% |
Net Profit Margin | -1.47% | ↑ 1.02% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 53.4M | ↓ 14.63% |
Net Income | -3.4M | ↑ 271.88% |
Net Profit Margin | -6.41% | ↓ 4.94% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 47.8M | ↓ 10.5% |
Net Income | 2.0M | ↓ 158.43% |
Net Profit Margin | 4.19% | ↑ 10.6% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 44.3M | ↓ 7.24% |
Net Income | -3.2M | ↓ 261.35% |
Net Profit Margin | -7.28% | ↓ 11.47% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 40.6M | ↓ 8.41% |
Net Income | -5.0M | ↑ 54.01% |
Net Profit Margin | -12.25% | ↓ 4.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 10.9M | ↓ 9.71% |
Net Income | -840.9K | ↑ 56.63% |
Net Profit Margin | -7.73% | ↓ 3.28% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.2M | ↓ 15.14% |
Net Income | -1.2M | ↑ 48.3% |
Net Profit Margin | -13.5% | ↓ 5.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.4M | ↓ 8.63% |
Net Income | -2.4M | ↑ 90.94% |
Net Profit Margin | -28.22% | ↓ 14.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.4M | ↑ 10.83% |
Net Income | -528.0K | ↓ 77.82% |
Net Profit Margin | -5.65% | ↑ 22.57% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.2M | ↓ 12.84% |
Net Income | -1.0M | ↑ 91.56% |
Net Profit Margin | -12.41% | ↓ 6.76% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 7.7M | ↓ 6.05% |
Net Income | -667.7K | ↓ 33.98% |
Net Profit Margin | -8.72% | ↑ 3.69% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 42.1M | ↑ 61.35% |
Total Liabilities | 20.7M | ↑ 50.49% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 39.6M | ↓ 5.76% |
Total Liabilities | 18.9M | ↓ 8.71% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 27.6M | ↓ 30.42% |
Total Liabilities | 7.7M | ↓ 59.32% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 39.1M | ↑ 41.94% |
Total Liabilities | 13.6M | ↑ 77.44% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 35.4M | ↓ 9.47% |
Total Liabilities | 13.7M | ↑ 0.8% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 30.1M | ↓ 15.16% |
Total Liabilities | 13.2M | ↓ 3.85% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 35.0M | ↑ 0.01% |
Total Liabilities | 14.5M | ↑ 5.97% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 33.4M | ↓ 4.42% |
Total Liabilities | 14.2M | ↓ 2.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 30.1M | ↓ 10.1% |
Total Liabilities | 13.2M | ↓ 7.16% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 30.3M | ↑ 0.94% |
Total Liabilities | 13.8M | ↑ 4.51% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 29.3M | ↓ 3.45% |
Total Liabilities | 13.8M | ↓ 0.24% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 27.8M | ↓ 5.24% |
Total Liabilities | 12.9M | ↓ 6.17% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 761.8K | ↓ 149.85% |
Investing Cash Flow | -9.3M | ↑ 1.0% |
Financing Cash Flow | 10.0M | ↓ 0.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 325.7K | ↓ 57.25% |
Investing Cash Flow | -224.1K | ↓ 97.59% |
Financing Cash Flow | -1.5M | ↓ 115.46% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.1M | ↑ 848.71% |
Investing Cash Flow | -292.4K | ↑ 30.45% |
Financing Cash Flow | -737.1K | ↓ 52.19% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 383.0K | ↓ 87.6% |
Investing Cash Flow | 1.5M | ↓ 623.74% |
Financing Cash Flow | 2.0M | ↓ 374.46% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↓ 1375.2% |
Investing Cash Flow | -317.8K | ↓ 120.76% |
Financing Cash Flow | -350.0K | ↓ 117.3% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 372.0K | ↓ 107.62% |
Investing Cash Flow | -186.9K | ↓ 41.21% |
Financing Cash Flow | -333.0K | ↓ 4.86% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -72.6K | ↓ 119.93% |
Investing Cash Flow | -106.7K | ↑ 439.2% |
Financing Cash Flow | -90.1K | ↓ 1.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 112.6K | ↓ 255.17% |
Investing Cash Flow | -9.8K | ↓ 90.84% |
Financing Cash Flow | -77.9K | ↓ 13.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -33.0K | ↓ 129.3% |
Investing Cash Flow | -9.8K | ↑ 0.0% |
Financing Cash Flow | -74.0K | ↓ 5.01% |
Sell
Neutral
Buy
Dynatronics Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Dynatronics Corp | -7.27% | -25.25% | -49.75% | -93.33% | -94.27% |
Stryker Corporation | 4.27% | 16.65% | 22.1% | 34.77% | 82.03% |
Boston Scientific Corp. | 4.07% | 37.85% | 46.89% | 79.63% | 93.34% |
Edwards Lifesciences Corp. | 3.26% | 27.0% | 2.23% | -8.36% | 51.45% |
Abbott Laboratories | -2.62% | -2.21% | -0.86% | -5.87% | 32.8% |
Medtronic Plc | 0.44% | 2.96% | -1.92% | -33.69% | -13.02% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Dynatronics Corp | NA | NA | 0.0 | -0.92 | -0.26 | -0.08 | NA | 1.41 |
Stryker Corporation | 38.89 | 38.89 | 2.92 | 11.96 | 0.19 | 0.07 | 0.01 | 50.33 |
Boston Scientific Corp. | 63.5 | 63.5 | 1.8 | 2.33 | 0.09 | 0.05 | NA | 13.56 |
Edwards Lifesciences Corp. | 37.45 | 37.45 | 5.19 | 2.76 | 0.21 | 0.12 | NA | 11.82 |
Abbott Laboratories | 31.83 | 31.83 | 5.99 | 4.63 | 0.15 | 0.06 | 0.02 | 22.31 |
Medtronic Plc | 29.48 | 29.48 | 1.52 | 5.2 | 0.07 | 0.04 | 0.03 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Dynatronics Corp | Buy | $2.1M | -94.27% | NA | -13.07% |
Stryker Corporation | Buy | $129.9B | 82.03% | 38.89 | 16.03% |
Boston Scientific Corp. | Buy | $111.1B | 93.34% | 63.5 | 12.05% |
Edwards Lifesciences Corp. | Buy | $52.4B | 51.45% | 37.45 | 23.01% |
Abbott Laboratories | Buy | $177.8B | 32.8% | 31.83 | 13.96% |
Medtronic Plc | Buy | $106.7B | -13.02% | 29.48 | 11.36% |
Renaissance Technologies Corp
Susquehanna International Group, LLP
Albion Financial Group (Utah)
Vanguard Group Inc
Tower Research Capital LLC
BlackRock Inc
dynatronics manufactures, markets, and distributes advanced-technology medical devices, treatment tables, and rehabilitation - acute-care - sport medicine - chiropractic - massage equipment as well as over 8,000 products and supplies. in addition, dynatronics has the most experienced and knowledgeable sales force in the industry. with more than 60 sales representatives and 150 active distributors located throughout the country, we are able to provide immediate service. dynatronics has built a solid reputation over the past 31 years for competitive pricing, excellent customer service, and unmatched clinical support. our field support team handles everything from equipment set-up to in-service training.
Organization | Dynatronics Corp |
Employees | 154 |
CEO | Mr. Brian D. Baker |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.43
+8.84%
Keyarch Acquisition Corp
$0.43
+8.84%
Connexa Sports Technologies Inc
$0.43
+8.84%
Us Value Etf
$0.43
+8.84%
First Wave Biopharma Inc
$0.43
+8.84%
Global X Msci Next Emerging
$0.43
+8.84%
Fat Projects Acquisition Corp
$0.43
+8.84%
Goal Acquisitions Corp
$0.43
+8.84%
Capital Link Global Fintech
$0.43
+8.84%